Cadre (CDRE) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
13 Aug, 2026Company overview and business model
Manufactures highly engineered safety equipment for professionals, with 85% of 2025 revenue from products and 15% from distribution.
Serves over 23,000 first responders and federal agencies in 104+ countries, with 2,600+ employees and 21 manufacturing facilities.
Focuses on duty gear, EOD, body armor, and nuclear safety, with a strong foundation in innovation and operational excellence.
Implements a leadership-centric operating model emphasizing lean processes, continuous improvement, and talent development.
Products have saved 2,281 lives as of August 2026.
Financial performance and outlook
Total revenue grew 88% and adjusted EBITDA grew 144% from FY2020 to FY2026E, with 430 bps margin expansion.
Q2 2026 net sales increased 32% YoY to $207.1M, with gross profit up 36% and adjusted EBITDA up 56%.
FY2026 guidance raised: net sales $749M–$769M, adjusted EBITDA $139M–$144M, capital expenditures $10M–$14M.
Net leverage at 2.5x as of June 30, 2026, with $53.9M in cash and $374.3M in total debt.
165% total shareholder return since IPO.
Growth strategy and M&A
Completed seven acquisitions since 2022, targeting strong margins, recurring revenues, and defensible market positions.
Recent acquisitions include Alien Gear Holsters, TYR Tactical, Alpha Safety, Carr's Engineering, ICOR, Cyalume, and Radar 1957.
M&A strategy focuses on expanding product suite, geographic reach, and entering new verticals with attractive ROIC.
Over $400M deployed in targeted M&A since January 2024, maintaining a robust pipeline in public safety and nuclear.
Latest events from Cadre
- Q2 2026 net sales rose 32%, with record backlog and raised guidance on strong demand.CDRE
Q2 2026 - Record backlog and robust growth in safety and nuclear markets drive strong 2026 outlook.CDRE
Investor presentation - Supplement amends 2025 executive compensation details; all other proxy matters remain unchanged.CDRE
Proxy filing - Q1 2026 net sales up 19%, record backlog, and major acquisitions support strong outlook.CDRE
Q1 2026 - Proxy covers director elections, auditor ratification, executive pay, and governance practices.CDRE
Proxy filing - Strong FY2025 results and disciplined M&A fuel growth, with FY2026 sales guidance up to $758M.CDRE
Investor presentation - Record EBITDA and net income growth in 2025, with double-digit 2026 outlook and higher dividend.CDRE
Q4 2025 - Nuclear safety and engineered products drive growth, margin expansion, and resilience.CDRE
Investor Day 2025 - Apex armor and robotics launches showcase innovation and global expansion focus.CDRE
Investor Update